Conference Proceedings
Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years
Gilles Andre Salles, John Francis Seymour, Pierre Feugier, Fritz Offner, Armando Lopez-Guillermo, David Belada, Luc Xerri, Reda Bouabdallah, John Catalano, Pauline Brice, Corinne Haioun, Alejandro Martin, Lars Moller Pedersen, Alain Jacques Delmer, David Simpson, Sirpa Leppa, Pierre Soubeyran, Rene-Olivier Casasnovas, Tanin Intragumtornchai, Vincent Ribrag Show all
BLOOD | AMER SOC HEMATOLOGY | Published : 2017
Grants
Funding Acknowledgements
Salles: Gilead: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Kite: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Servier: Consultancy, Honoraria; BMS: Consultancy; morphosys: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding. Feugier: Roche: Consultancy, Honoraria, Research Funding. Lopez-Guillermo: Celgene: Consultancy; Gilead: Consultancy; Janssen: Consultancy; Novartis: Consultancy; Roche: Consultancy, Other: Research grant. Belada: Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grants, Research Funding, Speakers Bureau; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grants, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grants, Speakers Bureau; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grants, Speakers Bureau. Haioun: Amgen: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Sandoz: Consultancy, Honoraria; JANSSEN: Consultancy, Honoraria; GILEAD: Consultancy, Honoraria; PFIZER: Consultancy, Honoraria. Martin: Gilead: Consultancy; Janssen: Honoraria; Servier: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Roche: Consultancy, Honoraria. Delmer: Roche: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Janssen: Honoraria; Gilead: Consultancy, Honoraria. Simpson: Onyx: Research Funding; Celgene: Honoraria, Other: travel expenses; Pharmacyclics LLC, an AbbVie Company: Research Funding; Amgen: Research Funding; Roche: Honoraria. Leppa: Roche: Consultancy, Honoraria, Research Funding; Bayer: Research Funding; Janssen Cilag: Consultancy, Research Funding; Merck: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Research Funding. Soubeyran: CELGENE: Honoraria; TEVA: Honoraria; Roche: Research Funding; Pierre Fabre: Honoraria; SPECTRUM: Honoraria. Ribrag: Roche: Honoraria, Other: travel, accommodation, expenses; BMS: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Infinity: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Nanostring: Consultancy, Honoraria; Epizyme: Consultancy, Honoraria; Pharmamar: Consultancy; Esai: Honoraria, Research Funding; ArgenX: Research Funding; Servier: Consultancy, Honoraria. Estell: Janssen: Membership on an entity's Board of Directors or advisory committees. Assemat: LYSARC: Employment. Zeuner: Roche: Employment. Coiffier: Celltrion, Inc: Consultancy, Honoraria. Tilly: Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria; Gilead: Honoraria; Immunogen: Honoraria; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.